Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "ERIBULIN MESILATE INJECTION"2024.12.11
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO GLOBAL COLLABORATION AGREEMENT WITH BIOSION AND ACLARIS THERAPEUTICS2024.12.05
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20242024.12.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR THE INDICATION OF TREATMENT FOR ENDOMETRIAL CANCER2024.11.27
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA2024.11.21
-
VOLUNTARY ANNOUNCEMENT - SIGNING EQUITY INVESTMENT AND STRATEGIC COOPERATION AGREEMENT WITH LANOVA MEDICINES2024.11.20
-
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY2024.11.18
-
VOLUNTARY ANNOUNCEMENT - APPROVAL GRANTED FOR CLINICAL TRIALS OF THE FOURTH-GENERATION EGFR INHIBITOR "TQB3002" IN THE UNITED STATES2024.11.14